98 related articles for article (PubMed ID: 10658444)
1. [Circadian variations of cutaneous blood flow in normal subjects and in patients with peripheral arteriopathies. Effect of PGE1 and alpha-cyclodextrin].
Laurora G; Belcaro G
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):45-9. PubMed ID: 10658444
[TBL] [Abstract][Full Text] [Related]
2. [Increasing transcutaneous PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin].
Belcaro G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):37-43. PubMed ID: 10658443
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
Bucci M; Iacobitti P; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
[TBL] [Abstract][Full Text] [Related]
4. [Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin].
Belcaro G; Bucci M; Cesarone MR; Incandela L; De Sanctis MT
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):51-4. PubMed ID: 10658445
[TBL] [Abstract][Full Text] [Related]
5. ["Responders and non-responders" to PGE1 and alpha-cyclodextrin].
De Sanctis MT; Incandela L; Iacobitti P
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):31-6. PubMed ID: 10658442
[TBL] [Abstract][Full Text] [Related]
6. [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
Laurora G; Corsi M; Bucci M; Cesarone MR; Belcaro G; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):21-9. PubMed ID: 10658441
[TBL] [Abstract][Full Text] [Related]
7. [Global analysis of data from studies with PDE1 alpha-cyslodextrin].
Laurora G; Belcaro G; Cesarone MR; Incandela L; De Sanctis MT; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):65-8. PubMed ID: 10658448
[TBL] [Abstract][Full Text] [Related]
8. [Intra-arterial infusion of PGE1 alpha cyclodextrin].
Laurora G; Cesarone MR; Belcaro G; Incandela L; De Sanctis MT; Fascetti E; D'Archivio C
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):17-20. PubMed ID: 10658440
[TBL] [Abstract][Full Text] [Related]
9. [Cardiovascular morbidity/mortality modified by the use of FGE1 alpha-cyclodextran and calcium heparin in patients with severe vascular diseases].
Belcaro G; Cesarone MR; Bucci M; Iacobitti P; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):55-8. PubMed ID: 10658446
[TBL] [Abstract][Full Text] [Related]
10. Effects of intravenous lipoprostaglandin E1 on neurogenic intermittent claudication.
Murakami M; Takahashi K; Sekikawa T; Yasuhara K; Yamagata M; Moriya H
J Spinal Disord; 1997 Dec; 10(6):499-504. PubMed ID: 9438815
[TBL] [Abstract][Full Text] [Related]
11. Short-range intermittent claudication and rest pain: microcirculatory effects of pentoxifylline in a randomized, controlled trial.
Incandela L; De Sanctis MT; Cesarone MR; Belcaro G; Nicolaides AN; Geroulakos G; Ramaswami G
Angiology; 2002; 53 Suppl 1():S27-30. PubMed ID: 11865832
[TBL] [Abstract][Full Text] [Related]
12. Circadian variation of skin perfusion in arterial occlusive disease.
Caspary L; Nordbruch S; Lange R; Creutzig A
Vasa; 1997 Aug; 26(3):194-8. PubMed ID: 9286151
[TBL] [Abstract][Full Text] [Related]
13. [Intramuscular injections of PGE1 in patients with severe claudication].
Corsi M; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):59-63. PubMed ID: 10658447
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].
Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Geroulakos G; Ramaswami G; Cazaubon M; Barsotti A; Vasdekis S; Christopoulos D; Agus G; Bavera P; Mondani P; Ippolito E; Flenda F
Minerva Cardioangiol; 2002 Dec; 50(6):683-90. PubMed ID: 12473989
[TBL] [Abstract][Full Text] [Related]
15. Ocular and orbital blood flow velocity in patients with peripheral vascular disease and diabetes treated with intravenous prostaglandin E1.
Steigerwalt RD; Belcaro GV; Christopoulos V; Incandela L; Cesarone MR; De Sanctis MT
J Ocul Pharmacol Ther; 2001 Dec; 17(6):529-35. PubMed ID: 11777176
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin therapy of peripheral occlusive arterial disease.
Linhart J
Sb Lek; 1998; 99(4):355-62. PubMed ID: 10803275
[TBL] [Abstract][Full Text] [Related]
17. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974333
[No Abstract] [Full Text] [Related]
18. A placebo-controlled study of the effects of intravenous Buflomedil on foot skin microcirculation in patients with severe intermittent claudication.
Van den Brande P; Maurel A
Angiology; 1998 Feb; 49(2):105-14. PubMed ID: 9482510
[TBL] [Abstract][Full Text] [Related]
19. Enhancing foot skin blood flux in peripheral vascular disease using intermittent pneumatic compression: controlled study on claudicants and grafted arteriopaths.
Delis KT; Husmann MJ; Nicolaides AN; Wolfe JH; Cheshire NJ
World J Surg; 2002 Jul; 26(7):861-6. PubMed ID: 12096335
[TBL] [Abstract][Full Text] [Related]
20. Behavior of calf blood flow in normal subjects and in patients with intermittent claudication during a 24-h time span.
Bartoli V; Dorigo B; Tedeschi E; Biti G; Voegelin MR
Chronobiologia; 1975; 2(1):13-9. PubMed ID: 1192904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
